Cancer Immunology, Immunotherapy
Title Abbreviation
Cancer Immunol Immunother
Electronic ISSN
1432-0851
Readership
Biologists, Hematologists, Immunologists, Oncologists
Scope
Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.
Sponsoring Association(s)
Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), Cancer Immunotherapy Immunomonitoring (CITIM), Italian Network for Cancer Biotherapy (Network Italiano per la Bioterapia dei Tumori) (NIBIT), Japanese Association for Cancer Immunology (JACI), Spanish Society of Immunology Immunotherapy Spanish-Group (Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia) (SEI-GEIT)
Publisher Name
Springer-Verlag GmbH & Co. KG-Heidelberg
To see more details about Cancer Immunology, Immunotherapy,
Subscribe Now!
Impact Factor
Circulation
Electronic Circulation
Submission to Acceptance
Acceptance to Online Publication
Acceptance to Print Publication
Rejection Rate
Frequency
Journal Contact
Author Submission Guidelines